AKT1 and chronic myelogenous leukemia, BCR-ABL1 positive: S1g-2, an inhibitor of the Hsp70–Bim interaction developed by Song et al., has shown antitumor effects in vitro and in vivo by disrupting AKT, Raf-1, and other kinases, especially in TKI-resistant CML [180].